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Role of the angiotensin II type 2 receptor in À ow (shear stress)- 
dependent remodelling of resistance arteries
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Grenier, Bertrand Toutain, Laurent Loufrani, Daniel Henrion
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Resistance arteries (RA) control local blood À ow. Chronic increases in 
blood À ow induce diameter enlargement (outward hypertrophic remodeling) 
of RA in response to growth, pregnancy, exercising as well as to compensate 
ischemia. Flow- mediated outward remodeling of RA declines with age in male 
rats, not in female rats. The angiotensin II type 2 receptor (AT2R) is involved 
in À ow- mediated dilation. It is also overexpressed in females and opposes high 
blood pressure. Thus, we hypothesized that AT2R and/or estrogens might play 
a role in remodeling.
A surgical model eliciting an local increase in blood À ow in one mesen-
teric RA without other changes in pressure or circulating factors was per-
formed in three- month old ovariectomized female rats treated or not with 
17- beta- estradiol (E2). Changes in RA diameter were measured after 2 weeks 
and several mechanisms of remodeling were assessed after 2 or 4 days.
After 2 weeks, arterial diameter increases in high À ow (HF) compared 
to normal À ow (NF) arteries in young ovariectomized rats treated with E2 
(458±12 vs 374±8m); not in untreated rats. The kinetics of inÀ amma-
tory markers, macrophage in¿ ltration, oxidative stress and MMPs activation 
involved in remodeling were not inÀ uenced by E2 depletion. In contrast, E2 
was required for the transient increase in AT2R expression (day 2), as well as 
the decrease in MYPT expression accompanied by an increased SHP1 expres-
sion at day 4. SHP1 is one of the major target proteins following AT2R sti-
mulation, which in turn inhibits MYPT. Furthermore, HF- remodeling did not 
occur in rats treated with the AT2R blocker PD12319.
Thus, we demonstrated the essential role of E2 in blood À ow- mediated 
remodeling of resistance arteries through the activation of AT2R.
0163
Galectin- 3 is a potential mediator of aldosterone effects in vascular re-
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Background: Aldosterone (Aldo) is involved in extracellular matrix (ECM) 
remodeling and inÀ ammation leading to heart failure (HF), but its mechanisms 
remains unknown. Galectin- 3 (Gal- 3), a β- galactosidase- binding lectin, plays 
an important role in inÀ ammation and HF. We have investigated whether 
Gal- 3 mediates Aldo- induced ECM remodeling in vascular smooth muscle 
cells (VSMCs) in vitro and in vivo.
Methods: Primary cultured VSMCs were stimulated with Aldo (10- 
8M) for 24h, with or without mineralocorticoid receptor (MR) antago-
nists (eplerenone, RU28318) and Gal- 3 inhibitors (modi¿ ed citrus pectin, 
N- acetyllactosamine, lactose). Gal- 3 was over- expressed (transfection) and 
knocked- down (siRNA). Wistar rats were treated with Aldo (1mg/kg/day)+salt 
or Aldo+salt+spironolactone (200mg/kg/day) for 3 weeks. Gal- 3 expression, 
ECM production (collagen type I and III, ¿ bronectin and elastin) and degrada-
tion (MMP activities) were evaluated by RT- PCR, Western blot, zymography 
and immunohistochemistry in VSMCs and aorta.
Results: Gal- 3 was spontaneously expressed in cultured VSMCs. Its over- 
expression enhanced collagen type I production. Aldo up- regulated Gal- 3 
levels in a dose- and time- dependent manner via the mineralocorticoid 
receptor. Gal- 3 chemical inhibitors blocked Aldo- induced ECM protein pro-
duction. In addition, Gal- 3 silencing abolished Aldo- induced collagen type I 
synthesis. In Aldo- salt hypertensive rats, aortic Gal- 3 expression, ECM pro-
teins and MMP activities were enhanced. Spironolactone treatment reversed 
all the above effects. Aortic Gal- 3 expression was positively correlated with 
vascular collagen type I, elastin, MMP- 2 and MMP- 13 activities.
Conclusions: Aldo up- regulates Gal- 3 expression via its mineralocorticoid 
receptor in VSMCs in vitro and in vivo. Gal- 3 over- expression induces col-
lagen type I synthesis. Moreover, Gal- 3 is required for the ¿ brotic response 
to Aldo. Our data suggest a key role for Gal- 3 in Aldo- induced vascular col-
lagen accumulation.
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Role of smooth muscle cell mineralocorticoid receptors in vascular tone 
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Arterial stiffness is a risk factor for the development of hypertension. 
This leads to arterial remodeling and increased damage after heart attack. 
Aldosterone is a main regulator of renal sodium reabsorption, modulating 
blood pressure (BP) by binding to mineralocorticoid receptors (MR). In cli-
nical trials, MR antagonists have bene¿ cial effects on cardiovascular without 
changes in BP suggesting effects of MR in the cardiovascular system.
MR speci¿ c contribution in vSMC to regulate muscular tone remains to be 
established. To address this question, we generated a mouse model with condi-
tional inactivation of the MR in SMC.
We ¿ rst con¿ rmed SMC- speci¿ c deletion of MR in vessels. The mutant mice 
had a similar carotid MCSA and elasticity as control mice, but with reduced 
BP (107.4±2.1 vs. 117.3±1.8mmHg in control, p<0.01) and decreased systolic 
diameter of carotid (0.55±0.02 vs. 0.61±0.02mm in control, p<0.05). Aortic 
contraction induced by phenylephrine was increased in the mutant mice (Emax: 
4.79±0.62 vs. 3.21±0.38mN in control, P<0.05) while contraction induced by 
KCL was reduced (Emax: 8.71±0.51 vs. 10.38±0.48mM in control, P<0.05). 
Relaxation induced by sodium nitroprussiate but not acetylcholine (ACh) was 
reduced (92±3 vs. 101±1% in control, P<0.05). However, the relaxing effect of 
acetylcholine was signi¿ cantly decreased in mutant compared to control mice 
in presence of indomethacin (Emax: 87±3 vs. 104±2% in control, P<0.01). The 
results show an alteration of vascular tone via a defect in the NO response. 
Microarray analysis showed an overrepresentation of Gene Ontology terms 
related to mitochondrial activity (NADH dehydrogenase and cytochrome- c 
oxidase activities), and muscle phenotype (collagen metabolic process).
vSMC- MR plays a role in the regulation of vascular tone as regulator 
of genes involved in the metabolic process (mitochondria and extracellular 
matrix organization). In basal condition, these changes have no impact on the 
arterial stiffness.
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Testing the Guyton- based cardiovascular- renal model of BP regulation 
against clinical data: re¿ nement of the endocrine renin- angiotensin sys-
tem and addition of ACE I/D polymorphism
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Population- wise, inhibitors of the renin- angiotensin system (RAS) are 
bene¿ cial in hypertension and CV & renal disease and widely used. In indi-
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viduals, genetic variants add more variability: among them the ACE I/D poly-
morphism can inÀ uence etiology and treatment. Computer modeling has 
emerged as a mandatory tool to handle complexity and explore hypotheses. We 
reprogrammed and updated Guyton Circulatory Model (CM) of BP homeos-
tasis with more realistic features including an endocrine RAS (Guillaud et 
Hannaert, 2010; Hernandez et al, 2011). However, as such it represents an ill- 
de¿ ned “subject” and cannot target clinical issues. Thus we started its pro-
gressive testing against human biochemical & physiological data. Here: (i) by 
exploiting new data, we improve RAS module (& enzyme parameters), yiel-
ding a re¿ ned model rCM, which (ii) we split according to ACE variants to 
confront to clinical data.
Methods: Modeling tools as in refs above. Biochemical data from BRENDA 
(brenda- enzymes. org) & selected papers. Parameter adjustment: data taken 
from human sources, in a selected corpus (+60 refs). Model testing: normo-
tensive data, Weekers et al, 2005 (We05) & Van der Kleij et al, 2002 (Vk02). 
Simulations at 150mEq/d Na intake; values given at steady- state (5 d).
Results: 1) RAS re¿ nement: rCM simulated variables fall within experi-
mental range (except for plasma Ang 1 and 2, < clinics) and rCM reproduces 
data from clinical controls (We05, Vk02); 2) Spliting the model into 2 ACE- 
instances (“II”=0.5 x “non- II”) has little bearing upon variables; similar obser-
vation is made when simulating chronic ACE inhibition by ramipril (as We05).
Discussion: We attempted to model the CVR consequences of ACE 
variants. At present, our model (and its genotyped instances) reproduces CVR 
& clinical data under (respective) normal conditions. Further improvements 
are needed for (i) better description of circulating angiotensins, (ii) ACE 
variant- driven behavior (eg. salt- dependent).
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Introduction: Atrial ¿ brillation (AF) is the most common complication 
after cardiac surgery and is responsible for signi¿ cant morbidity and mortality. 
To assess whether preconditioning with renin- angiotensin- aldosterone system 
agents could limit myocardial tissue injury, we tested the force of contraction 
of human right atrial trabeculae during hypoxia- reoxygenation when exposed 
to aldosterone and/or potassium canrenoate.
Materials and methods: We studied the effect of aldosterone and/or mine-
ralocorticoid receptor (MR) antagonist potassium canrenoate administration 
prior to hypoxia- reoxygenation and in normoxic condition on force of contrac-
tion in 51 human right atrial trabeculae obtained from patients scheduled for 
coronary artery bypass surgery or aortic valve replacement. We also tested if 
adosterone exposure results in changes in levels of ERK1/2 phosphorylation.
Results: The force of contraction of trabeculae was signi¿ cantly reduced by 
aldosterone administration under normoxic or hypoxia- reoxygenation condi-
tions. The rapid onset of this effect – 25 minutes – suggests a nongenomic 
mechanism. When compared with controls, potassium canrenoate by itself was 
not able to induce cardioprotection. However, coadministration of aldosterone 
and potassium canrenoate preconditioned isolated human atrial myocardium 
exposed to hypoxia–reoxygenation. This effect could be MR- dependent or not 
because both aldosterone and potassium canrenoate have some nongenomic 
MR- independent actions. Preliminary results showed that aldosterone expo-
sure increased ERK1/2 phosphorylation levels.
Conclusion: Potassium canrenoate- induced cardioprotection prevents the 
deleterious effect of aldosterone on human atrial myocardial tissue. Further 
research required to determine the mechanism involved and the potential 
bene¿ cial in clinical practice in order to reduce the incidence of postopera-
tive atrial ¿ brillation.
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Activation of cardiomyocyte mineralocorticoid by aldosterone affects 
both cardiomyocyte and non- cardiomyocyte cells
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Aims: Inappropriate mineralocorticoid receptor (MR) activation is involved 
in cardiac diseases. Whether aldosterone is responsible for the deleterious 
effects of cardiac MR activation is still unclear.
 Methods and Results: Mice overexpressing MR in cardiomyocytes (MR- 
Cardio) and their controls (Ctrl) were treated for 7 days with aldosterone and 
a cardiac whole genome microarray analysis was performed. 
Aldosterone regulated 89 genes in Ctrl mice and 265 in MR- Cardio mice. 
Among these genes, several were already differentially expressed between 
MR- Cardio and Ctrl mice such as CTGF. In MR- Cardio mice, aldosterone 
induced an increase of CTGF mRNA (x3, p<0.05) and protein (x3, p<0.05) in 
cardiomyocytes. In vitro (H9C2 cells), aldosterone induced CTGF expression 
in a MR- dependent manner. 
To identify the biological processes modulated by aldosterone, a gene onto-
logy (GO) analysis was performed. The majority of aldosterone- regulated 
genes were involved in cell division. To con¿ rm this result, we assessed cell 
proliferation in cardiac sections of aldosterone- treated Ctrl and MR- Cardio 
mice. The Ki- 67 index of aldo- treated mice (Ctrl and MR- Cardio) was higher 
(x2 to 3, p<0.05) than in non- treated ones con¿ rming microarray predictions. 
In MR- Cardio mice, more cells were engaged in M phase (phospho- histone 
H3 index). Co- staining of Ki- 67 with caveolin 1 revealed that most of cycling 
cells were endothelial. Both aldosterone induction of cardiomyocyte synthesis 
of CTGF and endothelial cell (EC) proliferation seem pathologically relevant 
as both were increased (x8 and x2 respectively, p<0.05) in an experimental 
model of heart failure (transverse aortic constriction) in rats. This increase was 
prevented by eplerenone, an MR blocker. 
Conclusion: Aldosterone can activate cardiomyocyte MR despite a large 
excess of endogenous glucocorticoids and regulate EC proliferation in vivo. 
Activation of cardiomyocyte- MR by aldosterone affects both cardiomyocyte 
and non- cardiomyocyte cells.
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